Regulus Therapeutics Inc (RGLS)
2.65
-0.04
(-1.49%)
USD |
NASDAQ |
May 03, 16:00
2.65
0.00 (0.00%)
After-Hours: 20:00
Regulus Therapeutics Cash from Operations (Quarterly): -6.125M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -6.125M |
| September 30, 2023 | -6.277M |
| June 30, 2023 | -6.252M |
| March 31, 2023 | -8.114M |
| December 31, 2022 | -6.253M |
| September 30, 2022 | -6.733M |
| June 30, 2022 | -6.159M |
| March 31, 2022 | -6.381M |
| December 31, 2021 | -7.831M |
| September 30, 2021 | -5.562M |
| June 30, 2021 | -5.024M |
| March 31, 2021 | -5.711M |
| December 31, 2020 | 3.189M |
| September 30, 2020 | -4.497M |
| June 30, 2020 | -5.226M |
| March 31, 2020 | -6.002M |
| December 31, 2019 | -4.977M |
| September 30, 2019 | -4.72M |
| June 30, 2019 | -5.691M |
| March 31, 2019 | -4.433M |
| December 31, 2018 | -4.017M |
| September 30, 2018 | -11.44M |
| June 30, 2018 | -12.21M |
| March 31, 2018 | -15.60M |
| Date | Value |
|---|---|
| December 31, 2017 | -11.10M |
| September 30, 2017 | -11.66M |
| June 30, 2017 | -17.33M |
| March 31, 2017 | -18.68M |
| December 31, 2016 | -15.11M |
| September 30, 2016 | -15.50M |
| June 30, 2016 | -17.34M |
| March 31, 2016 | -8.93M |
| December 31, 2015 | -17.04M |
| September 30, 2015 | -11.80M |
| June 30, 2015 | -9.763M |
| March 31, 2015 | -11.25M |
| December 31, 2014 | -11.66M |
| September 30, 2014 | -8.802M |
| June 30, 2014 | -10.02M |
| March 31, 2014 | -9.029M |
| December 31, 2013 | -9.314M |
| September 30, 2013 | -4.429M |
| June 30, 2013 | -7.432M |
| March 31, 2013 | -7.155M |
| December 31, 2012 | 0.851M |
| September 30, 2012 | 0.225M |
| June 30, 2012 | -4.669M |
| March 31, 2012 | -5.128M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-8.114M
Minimum
Mar 2023
3.189M
Maximum
Dec 2020
-5.492M
Average
-6.002M
Median
Mar 2020
Cash from Operations (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | 85.39M |
| ADMA Biologics Inc | 17.60M |
| FibroGen Inc | -18.32M |
| Protara Therapeutics Inc | -8.70M |
| Amylyx Pharmaceuticals Inc | 13.55M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 4.932M |
| Cash from Financing (Quarterly) | -0.873M |
| Free Cash Flow | -27.38M |
| Free Cash Flow Per Share (Quarterly) | -0.3062 |
| Free Cash Flow Yield | -54.52% |